Figure 6.
YL activates the 5-HT1A, dopamine D1, and GABAA systems. Effect of serotonin 5-HT1A, dopamine D1, and GABAA antagonist on YL-induced antidepressant-like activity. WAY100135 dihydrochloride, a serotonin 5-HT1A receptor antagonist (10 mg/kg), R(+)-SCH-23390 hydrochloride, a dopamine D1 receptor antagonist (30 mg/kg), or (−)-bicuculline (5 mg/kg) or flumazenil, antagonists of GABA- and benzodiazepine-binding sites of GABAA receptors, respectively (1 mg/kg), was co-administered once intraperitoneally with the peptide 30 min before FST. Values are expressed as the mean ± S.E.M. (n = 9–10). Different characters represent significant differences (P < 0.05) among each group by ANOVA followed by Tukey-Kramer’s test.